Regeneron Pharmaceuticals, Inc. confirmed that Regeneron provided a single 8-gram dose of REGN-COV2, a cocktail of two monoclonal antibodies for use by President Trump following a compassionate use request by White House physicians.  Compassionate use requests are approved under rare, exceptional circumstances on a case-by-case basis. 
 
REGN-COV2 is an investigational monoclonal antibody cocktail that is in clinical trials for the treatment and prevention of COVID-19. It consists of two potent, complementary virus-neutralizing antibodies and was designed specifically to target the SARS-CoV-2 virus. Preliminary data published earlier this week showed that REGN-COV2 reduced viral levels and improved symptoms in infected, non-hospitalized COVID-19 patients. 
 
Clinical trials of this medicine are actively enrolling at IACT Health right here in Columbus, Georgia. We are participating in the Regeneron outpatient treatment and prevention trials at our site. To learn more and see if you qualify to participate, contact us at 706-321-0495.